Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177–189. https://doi.org/10.1212/WNL.0000000000001729

Article  PubMed  PubMed Central  Google Scholar 

Cree BA, Bennett JL, Sheehan M et al (2016) Placebo-controlled study in neuromyelitis optica-ethical and design considerations. Mult Scler 22(7):862–872. https://doi.org/10.1177/1352458515620934

Article  CAS  PubMed  Google Scholar 

Misu T, Höftberger R, Fujihara K et al (2013) Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol 125(6):815–827. https://doi.org/10.1007/s00401-013-1116-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Petzold A (2015) Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease. Brain Res 1600:17–31. https://doi.org/10.1016/j.brainres.2014.12.027

Article  CAS  PubMed  Google Scholar 

Takano R, Misu T, Takahashi T et al (2010) Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 75(3):208–216. https://doi.org/10.1212/WNL.0b013e3181e2414b

Article  CAS  PubMed  Google Scholar 

Misu T, Takano R, Fujihara K et al (2009) Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry 80(5):575–577. https://doi.org/10.1136/jnnp.2008.150698

Article  CAS  PubMed  Google Scholar 

Schindler P, Aktas O, Ringelstein M et al (2023) Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review. Expert Rev Clin Immunol 19(1):71–91. https://doi.org/10.1080/1744666X.2023.2148657

Article  CAS  PubMed  Google Scholar 

Chang X, Huang W, Wang L et al (2021) Serum neurofilament light and GFAP are associated with disease severity in inflammatory disorders with aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies. Front Immunol 12:647618. https://doi.org/10.3389/fimmu.2021.647618

Article  CAS  PubMed  PubMed Central  Google Scholar 

Watanabe M, Nakamura Y, Michalak Z et al (2019) Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology 93(13):e1299–e1311. https://doi.org/10.1212/WNL.0000000000008160

Article  CAS  PubMed  Google Scholar 

Aktas O, Smith MA, Rees WA et al (2021) Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker. Ann Neurol 89(5):895–910. https://doi.org/10.1002/ana.26067

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schindler P, Grittner U, Oechtering J et al (2021) Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. J Neuroinflammation 18(1):105. https://doi.org/10.1186/s12974-021-02138-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang S, Zhang C, Zhang TX et al (2023) A real-world study of interleukin-6 receptor blockade in patients with neuromyelitis optica spectrum disorder. J Neurol 270(1):348–356. https://doi.org/10.1007/s00415-022-11364-9

Article  CAS  PubMed  Google Scholar 

Khalil M, Teunissen CE, Lehmann S et al (2024) Neurofilaments as biomarkers in neurological disorders - towards clinical application. Nat Rev Neurol 20(5):269–287. https://doi.org/10.1038/s41582-024-00955-x

Article  PubMed  Google Scholar 

Benkert P, Meier S, Schaedelin S et al (2022) Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol 21(3):246–257. https://doi.org/10.1016/S1474-4422(22)00009-6

Article  PubMed  Google Scholar 

Kim SH, Gomes ABAGR, Schindler P et al (2025) Blood-based biomarkers for identifying disease activity in AQP4-IgG-positive neuromyelitis optica spectrum disorder. JAMA Neurol 82(2):168–175. https://doi.org/10.1001/jamaneurol.2024.4400

Article  PubMed  Google Scholar 

Wang R, Sun D, Wang X et al (2024) Correlation between severe attacks and serum aquaporin-4 antibody titer in neuromyelitis optica spectrum disorder. J Neurol 271(7):4503–4512. https://doi.org/10.1007/s00415-024-12382-5

Article  CAS  PubMed  Google Scholar 

Chen H, Qiu W, Zhang Q et al (2017) Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. Eur J Neurol 24(1):219–226. https://doi.org/10.1111/ene.13186

Article  CAS  PubMed  Google Scholar 

Kuhle J, Barro C, Andreasson U et al (2016) Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 54(10):1655–1661. https://doi.org/10.1515/cclm-2015-1195

Article  CAS  PubMed  Google Scholar 

Liu C, Lu Y, Wang J et al (2021) Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: a cohort study. J Neurochem 159(5):913–922. https://doi.org/10.1111/jnc.15478

Article  CAS  PubMed  Google Scholar 

Kim H, Lee EJ, Kim S et al (2022) Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder. Mult Scler 28(4):512–521. https://doi.org/10.1177/13524585211024978

Article  CAS  PubMed  Google Scholar 

Aly L, Strauß EM, Feucht N et al (2022) Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders. Mult Scler 28(4):522–531. https://doi.org/10.1177/13524585211028831

Article  CAS  PubMed  Google Scholar 

Kim H, Lee EJ, Kim S et al (2020) Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease. Neurol Neuroimmunol Neuroinflamm 7(3):e708. https://doi.org/10.1212/NXI.0000000000000708

Article  PubMed  PubMed Central  Google Scholar 

Ventura RE, Kister I, Chung S, Babb JS, Shepherd TM (2016) Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions. Neurol Neuroimmunol Neuroinflamm 3(3):e224. https://doi.org/10.1212/NXI.0000000000000224

Article  PubMed  PubMed Central  Google Scholar 

Oertel FC, Kuchling J, Zimmermann H et al (2017) Microstructural visual system changes in AQP4-antibody-seropositive NMOSD. Neurol Neuroimmunol Neuroinflamm 4(3):e334. https://doi.org/10.1212/NXI.0000000000000334

Article  PubMed  PubMed Central  Google Scholar 

Ringelstein M, Harmel J, Zimmermann H et al (2020) Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. Neurology 94(4):e407–e418. https://doi.org/10.1212/WNL.0000000000008684

Article  PubMed  Google Scholar 

Lee EJ, Lim YM, Kim S et al (2020) Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases. Ann Clin Transl Neurol 7(6):992–1001. https://doi.org/10.1002/acn3.51070

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hyun JW, Kim Y, Kim G, Kim SH, Kim HJ (2020) Longitudinal analysis of serum neurofilament light chain: a potential therapeutic monitoring biomarker for multiple sclerosis. Mult Scler 26(6):659–667. https://doi.org/10.1177/1352458519840757

Article  CAS  PubMed  Google Scholar 

Kinoshita M, Nakatsuji Y, Kimura T et al (2010) Anti-aquaporin- 4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem